Completed PHASE3 INTERVENTIONAL 2-arm NCT00288418

Safety and Efficacy Study of Angiotech Central Venous Catheter to Prevent Bacterial Catheter Colonization

A Controlled, Randomized, Single-Blind, Multi-Center Pivotal Clinical Study Using Angiotech CVC to Prevent Bacterial Colonization on Short-Term Central Venous Catheters

Sponsor: Angiotech Pharmaceuticals

Conditions Bacterial Infections

Interventions Central Venous Catheter

Updated 6 times since 2017 Last updated: Jan 22, 2013 Started: Dec 31, 2005 Primary completion: Jul 31, 2007 Completion: Jul 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Bacterial Infections, this trial is completed. The trial is conducted by Angiotech Pharmaceuticals and has accumulated 6 data snapshots since 2005. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Dec 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Angiotech Pharmaceuticals

Data source: Angiotech Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Birmingham, United States , Charlottesville, United States , Cincinnati, United States , Decatur, United States , Denver, United States , Gainesville, United States , Newark, United States , Oklahoma City, United States , Opelousas, United States , Orange, United States and 9 more locations